Akeso details survival win for its PD-1xVEGF drug versus Keytruda

Data ReadoutpositivePD-1xVEGFKeytrudaPositive

AI Analysis

Summary

Akeso and Summit Therapeutics announced survival data from their PD-1xVEGF drug demonstrating a win versus Merck's Keytruda. The companies are detailing results from a key comparison trial started in early September.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Survival data win versus Keytruda

Importance:7/10

Sentiment:

0.70

PD-1 inhibitorVEGFImmunotherapySurvival dataClinical trial

Read the original article

Published by Endpoints News on September 13, 2026 1:46 AM

Read Original